<DOC>
	<DOCNO>NCT01308203</DOCNO>
	<brief_summary>- Clinical study statins show patient suffer cardiovascular event high residual risk . Residual risk decrease attain progressive low LDL-C level . - In patient treated statin , HDL-C level independent inverse predictor subsequent CV coronary plaque progression , even LDL-C level less 70 mg/dL . - Therefore purpose study assess lipid efficacy lipid profile effect HDL-C metabolism function extend release niacin/laropiprant combination add usual therapy high risk patient cardiovascular disease low HDL-C achieve optional low LDL-C non-HDL-C goal</brief_summary>
	<brief_title>Lipid Efficacy Extended Release Niacin/Laropiprant Combination Patients With Cardiovascular Disease</brief_title>
	<detailed_description>During screen period , patient pre-selected medical record patient meet inclusion criterion . Patients fulfil eligibility criterion invite participate study sign consent form . After consent , screen blood sample test take determine TC , HDL-C , TG , LDL-C , non-HDL-C ( difference TC HDL-C ) , ALT , AST , CK , hemoglobin A1c ( HbA1c ) , uric acid TSH local laboratory . Patients HDL-C , LDL-C and/or non-HDL-C within inclusion criterion none biochemical exclusion criterion randomize one week screen blood test . Further blood sample obtain baseline , 4 week ( ± 2 day ) , 12 week ( ± 2 day ) , 16 week ( ± 2 day ) 24 week ( ± 2 day ) . The blood sample centrifuge 2000 rpm tube blood serum send local laboratory measure plasma level TC , HDL-C , TG , LDL-C , ALT , AST , CK , fast glucose , HbA1c , creatinine , uric acid , ApoB , ApoA , Lp ( ) , high sensibility-C Reactive Protein ( hs-CRP ) HDL-C sub-fractions ( baseline , week 12 24 ) . ALT , AST , CK , fast glucose , creatinine uric acid measure week 4 16 . A second tube frozen -70ºC refrigerator send Department Clinical Biochemistry Faculty Pharmacy Biochemistry University Buenos Aires ( Argentina ) determine : paraoxonase 1/arylesterase activity ( PON1 ) , soluble cell adhesion molecule level ( ICAM-1 ) , tumor necrosis factor-α ( TNF-α ) , lipoprotein-associated phospholipase A2 ( Lp-PLA2 ) cholesterol ester transfer protein ( CETP ) activity . A third tube frozen -70ºC refrigerator send Cardiovascular Research Center Faculty Medical Sciences University La Plata ( Argentina ) determine ex vivo cellular cholesterol efflux capacity . A unique patient number provide randomization coordinate centre Hospital Italiano de Buenos Aires . Randomized patient receive bottle 35 pill 1g ERN/20mg LRPT placebo . At week 4 ( ± 2 day ) , randomization patient assess outpatient clinic . Patients good tolerance study medication receive four bottle 35 pill 1g ERN/20mg LRPT placebo . At week 12 ( ± 2 day ) , patient assess outpatient clinic patient cross placebo active medication . Patients receive bottle 35 pill 1g ERN/20mg LRPT placebo . At week 16 ( ± 2 day ) , patient good tolerance study medication receive four bottle 35 pill 1g ERN/20mg LRPT placebo .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Men 21 75 year old . Very high risk patient ( accord NCEPATP III definition ) coronary heart disease ( CHD ) peripheral arterial disease ( PAD ) , document angiographic study . Clinical stability . Low HDLC plasma level : &lt; 40 mg/dL men &lt; 50 mg/dL woman screen leadin blood sample test . LDLC plasma level 70100 mg/dL nonHDLC 100130 mg/dL TG &gt; 200 mg/dL screen leadin blood sample test . Statin basedtreatment without ezetimibe stable dose last 8 week . Women must postmenopausal least 2 year ≤ 75 year old . Coronary event arterial revascularization past 6 month . Uncontrolled diabetes mellitus ( HbA1C &gt; 8 % ) . Acute crisis , history gout uric acid &gt; 9 mg/dL . Thyroid stimulate hormone ( TSH ) outside central laboratory 's normal reference range . Renal insufficiency ( creatinine &gt; 1.5 mg/dL ) . Baseline alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) level &gt; 1.5 UNL . Baseline creatine kinase ( CK ) &gt; 2 UNL . Triglycerides plasma level ≥ 500 mg/dL . Active fibrate therapy . Age &gt; 75 year old .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>